Compare TDOC & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TDOC | GHRS |
|---|---|---|
| Founded | 2002 | 2018 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Medical/Nursing Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 947.2M |
| IPO Year | 2015 | 2021 |
| Metric | TDOC | GHRS |
|---|---|---|
| Price | $7.62 | $24.21 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 18 | 8 |
| Target Price | $7.56 | ★ $41.38 |
| AVG Volume (30 Days) | ★ 4.9M | 190.3K |
| Earning Date | 04-29-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 80.58 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,406,840,000.00 | N/A |
| Revenue This Year | $1.19 | N/A |
| Revenue Next Year | $1.25 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 18.41 | N/A |
| 52 Week Low | $4.40 | $10.96 |
| 52 Week High | $9.77 | $24.66 |
| Indicator | TDOC | GHRS |
|---|---|---|
| Relative Strength Index (RSI) | 73.51 | 66.60 |
| Support Level | $7.48 | $12.65 |
| Resistance Level | $7.95 | $24.66 |
| Average True Range (ATR) | 0.36 | 1.55 |
| MACD | 0.05 | -0.04 |
| Stochastic Oscillator | 76.84 | 92.71 |
Teladoc Health Inc is engaged in the provision of virtual healthcare services, connecting patients, providers, and healthcare systems through technology-enabled platforms. The company has two reportable segments: Integrated Care and BetterHelp. The Integrated Care segment provides virtual healthcare solutions, including primary care, mental health, chronic care management, and telehealth enablement services for employers, insurers, and healthcare systems, mainly on a business-to-business basis, while the BetterHelp segment offers direct-to-consumer online mental health services, including counseling and therapy delivered through digital platforms. It generates the majority of its revenue from the Integrated Care segment.
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.